FYERS
Home
/
Stocks
/
Results
/
Sudeep Pharma Results

Sudeep Pharma Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
-24%14%28%
-39%41%26%
----
33%34%35%25%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
SUDEEPPHRM
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,849.9₹447476 Cr3712.0762.82₹11479 Cr
9,602₹254764 Cr87.134.04128.41₹2568 Cr
4,928.5₹189423 Cr86.8516.7297.06₹2163 Cr
1,180.3₹116658 Cr25.859.4262.53₹5040 Cr
1,399₹111484 Cr33.089.7757.87₹3879 Cr
2,026.2₹109943 Cr100.556.829.25₹889 Cr
2,500₹101712 Cr49.7913.7571.08₹1913 Cr
1,200.4₹101005 Cr31.355.3263.99₹4196 Cr
1,716₹99253 Cr26.7317.9596.84₹3505 Cr
2,100.7₹96031 Cr17.3730.95154.35₹5333 Cr
1,143.4₹13545 Cr74.173.5917.55₹173 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
———————
₹11 Cr₹12 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr₹1 Cr
₹872 Cr₹481 Cr₹355 Cr₹222 Cr₹162 Cr₹113 Cr₹80 Cr
₹872 Cr₹481 Cr₹355 Cr₹222 Cr₹162 Cr₹113 Cr₹80 Cr
₹883 Cr₹493 Cr₹356 Cr₹223 Cr₹163 Cr₹114 Cr₹81 Cr
₹15 Cr₹0₹0₹0₹0₹0₹0
₹34 Cr₹40 Cr₹11 Cr₹20 Cr₹28 Cr₹14 Cr₹8 Cr
₹9 Cr₹6 Cr₹6 Cr₹5 Cr₹4 Cr₹4 Cr₹4 Cr
₹31 Cr₹2 Cr₹2 Cr₹54 L₹0₹0₹80,952
₹4 L₹2 Cr₹1 Cr₹38 L₹81 L₹1 Cr₹94 L
₹74 Cr₹49 Cr₹20 Cr₹25 Cr₹33 Cr₹19 Cr₹13 Cr
———————
₹68 Cr₹60 Cr₹51 Cr₹38 Cr₹27 Cr₹18 Cr₹9 Cr
₹29 Cr₹25 Cr₹25 Cr₹71 Cr₹1 Cr₹19 Cr₹10 Cr
₹102 Cr₹86 Cr₹54 Cr₹52 Cr₹55 Cr₹17 Cr₹9 Cr
₹2 Cr₹4 Cr₹7 Cr₹10 Cr₹63 Cr₹27 Cr₹9 Cr
₹202 Cr₹175 Cr₹137 Cr₹171 Cr₹147 Cr₹80 Cr₹37 Cr
₹1174 Cr₹717 Cr₹514 Cr₹420 Cr₹344 Cr₹213 Cr₹131 Cr
₹0₹10 L₹10 L₹10 L₹26 L₹26 L₹0
₹148 Cr₹135 Cr₹75 Cr₹82 Cr₹84 Cr₹31 Cr₹20 Cr
———————
₹378 Cr₹216 Cr₹197 Cr₹166 Cr₹157 Cr₹83 Cr₹72 Cr
₹41 Cr₹27 Cr₹17 Cr₹8 Cr₹20 Cr₹16 Cr₹12 Cr
₹337 Cr₹189 Cr₹180 Cr₹158 Cr₹137 Cr₹68 Cr₹60 Cr
₹178 Cr₹88 Cr₹45 Cr₹26 Cr₹8 Cr₹24 Cr₹8 Cr
₹0₹0₹0₹0₹0₹19 Cr₹6 Cr
₹0₹0₹0₹0₹0₹19 Cr₹6 Cr
₹13 Cr₹15 Cr₹13 Cr₹5 Cr₹2 Cr₹2 Cr₹79 L
₹15 Cr₹33 L₹32 L₹27 L₹0₹0₹0
₹550 Cr₹293 Cr₹238 Cr₹190 Cr₹147 Cr₹113 Cr₹75 Cr
———————
₹0₹14 L₹13 L₹3 Cr₹0₹0₹0
₹216 Cr₹129 Cr₹67 Cr₹71 Cr₹37 Cr₹17 Cr₹9 Cr
₹228 Cr₹185 Cr₹145 Cr₹94 Cr₹107 Cr₹55 Cr₹30 Cr
₹115 Cr₹52 Cr₹14 Cr₹10 Cr₹21 Cr₹12 Cr₹4 Cr
₹10 Cr₹19 Cr₹6 Cr₹4 Cr₹50 L₹32 L₹2 Cr
₹56 Cr₹39 Cr₹44 Cr₹48 Cr₹31 Cr₹15 Cr₹10 Cr
₹624 Cr₹424 Cr₹275 Cr₹230 Cr₹197 Cr₹99 Cr₹56 Cr
₹422 Cr₹249 Cr₹138 Cr₹59 Cr₹50 Cr₹20 Cr₹20 Cr
₹1174 Cr₹717 Cr₹514 Cr₹420 Cr₹344 Cr₹213 Cr₹131 Cr
₹78₹50₹2,527₹1,585₹1,159₹810₹574
₹78₹50₹37₹23₹17₹12₹8

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
₹228 Cr₹183 Cr₹175 Cr₹86 Cr₹69 Cr₹43 Cr₹25 Cr
₹9 Cr₹15 Cr₹13 Cr₹18 Cr₹5 Cr₹4 Cr₹4 Cr
-₹112 Cr-₹109 Cr-₹78 Cr-₹33 Cr-₹59 Cr-₹1 Cr-₹13 Cr
₹125 Cr₹89 Cr₹110 Cr₹71 Cr₹15 Cr₹46 Cr₹16 Cr
₹70 Cr₹49 Cr₹66 Cr₹48 Cr-₹3 Cr₹35 Cr₹10 Cr
-₹331 Cr-₹79 Cr-₹49 Cr-₹50 Cr-₹38 Cr-₹40 Cr-₹22 Cr
₹247 Cr₹53 Cr-₹13 Cr-₹10 Cr₹51 Cr₹13 Cr₹12 Cr
-₹14 Cr₹23 Cr₹4 Cr-₹11 Cr₹10 Cr₹8 Cr-₹16 L
₹37 Cr₹14 Cr₹10 Cr₹21 Cr₹12 Cr₹4 Cr₹4 Cr
₹4 Cr₹0₹0₹0₹0₹0₹0
₹28 L₹16 L₹50,000₹23 L₹0₹0₹0
₹27 Cr₹37 Cr₹14 Cr₹10 Cr₹21 Cr₹12 Cr₹4 Cr

Fundamental Ratios

Consolidated
Standalone

Share Price Live Stats

Open (₹)1,180.10
Volume (₹)1.44 L
High (₹)1,193.00
Upper Circuit1,259.50
Low (₹)1,139.70
Lower Circuit1,139.70
Prev Close1,199.60
52W High (₹)1,378.00
Price1,143.40
52W Low (₹)524.05

Share Market Cap & Key Ratios Overview

M.Cap (₹)13545.40 Cr
Div. Yield (%)0.13
PE Ratio74.17
Debt to Equity0.17
Price to Book7.57
Book Value78.21
EPS (TTM)16.17
Face Value1.00
ROE (%)25.37

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
SUDEEPPHRMNSE
LTP
1W Low
1W High
Market cap (₹)
1849.9+12.6 (0.69%)
1832.20
1891.50
4,47,476Cr
9602+227 (2.42%)
9312.50
9740
2,54,764Cr
4928.5+88.5 (1.83%)
4848.50
5010
1,89,423Cr
1180.3+20.3 (1.75%)
1152.10
1190.60
1,16,658Cr
1399+4.5 (0.32%)
1364.50
1419
1,11,484Cr
2026.2+72.2 (3.69%)
1963.80
2055.30
1,09,943Cr
2500+199.3 (8.66%)
2303
2504.30
1,01,712Cr
1200.4+15.4 (1.30%)
1185
1222
1,01,005Cr
1716-18 (-1.04%)
1689.30
1740
99,253Cr
2100.7+17.7 (0.85%)
2080
2135
96,031Cr
1143.4-11.6 (-1.00%)
1123.10
1210
13,545Cr

Sudeep Pharma Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹60.36Cr; with other income of ₹5.45Cr, profit before interest and tax came to ₹56.35Cr. Interest expense was ₹2.06Cr; PBT before exceptional items stood at ₹54.29Cr. Cost mix (full year): raw materials ₹263.98Cr; employee cost ₹51.89Cr; depreciation ₹4Cr; other expenses ₹103.36Cr. Basis: consolidated annual results.

Sudeep Pharma Ltd Quaterly Results Key Takeaways

Sudeep Pharma Ltd reported ₹158.27Cr total income from operations in Jun 2026, softer than ₹182.34Cr in Mar 2026 but higher than ₹124.92Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹60.36Cr; with other income of ₹5.45Cr, profit before interest and tax came to ₹56.35Cr. Interest expense was ₹2.06Cr, taking profit before tax to ₹54.29Cr. After tax of ₹13.71Cr, profit after tax stood at ₹40.59Cr (vs ₹48.54Cr in Mar 2026 and ₹31.27Cr in Jun 2025).